Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 30,704,000, an increase of 49% compared to HKD 20,599,000 for the same period in 2023[7] - Gross profit for the period was HKD 10,790,000, down from HKD 11,393,000 in the previous year, reflecting a decrease of approximately 5.3%[1] - The company reported a loss before tax of HKD 4,793,000, compared to a loss of HKD 2,658,000 in the same period last year, indicating a worsening of 80%[1] - Total comprehensive loss for the period was HKD 6,093,000, compared to HKD 3,401,000 in the previous year, representing an increase of 79.3%[1] - The company reported a loss attributable to owners of the company of HKD 6,093,000 for the six months ended June 30, 2024, compared to HKD 3,874,000 for the same period in 2023[15] - The consolidated loss attributable to the company was HKD 6.1 million, an increase from HKD 3.4 million in 2023, primarily due to fair value losses on financial assets[22] Assets and Liabilities - Current liabilities net amount was HKD 339,232,000, slightly improved from HKD 341,590,000 in the previous period[4] - Non-current assets, including property, plant, and equipment, increased to HKD 2,584,000 compared to HKD 238,000 at the end of 2023[2] - The total assets less current liabilities amounted to HKD 329,954,000, compared to HKD 320,615,000 in the previous period, showing a slight increase[4] - As of June 30, 2024, total assets amounted to HKD 50,132,000, with segment assets in the medical and health business at HKD 44,258,000[10] - The company’s total liabilities as of June 30, 2024, were HKD 380,086,000, with segment liabilities in the medical and health business at HKD 26,661,000[10] - As of June 30, 2024, total assets were HKD 50.1 million, down from HKD 56.1 million as of December 31, 2023, while total liabilities increased to HKD 330.0 million from HKD 323.9 million[23] Cash Flow and Financing - The net cash outflow from operating activities was HKD 11.4 million for the six months ended June 30, 2024, compared to HKD 9.0 million in 2023[23] - The group had a cash and bank balance of HKD 4.1 million as of June 30, 2024, down from HKD 8.1 million as of December 31, 2023[23] - The total borrowings amounted to HKD 295.3 million as of June 30, 2024, compared to HKD 290.8 million as of December 31, 2023[23] - The company has extended the maturity of a HKD 15,000,000 loan by six months to March 31, 2025, to improve liquidity[6] - The company has successfully implemented a plan to extend a loan of HKD 15,000,000 by six months to March 31, 2025[20] Business Operations - The company continues to develop its medical and health business to enhance its financial position[6] - For the six months ended June 30, 2024, the company reported external sales of HKD 20,599,000 in the medical and health business, with a total segment profit of HKD 7,995,000[10] - The company incurred a pre-tax loss of HKD 2,658,000 after allocating unallocated corporate expenses and financing costs of HKD 4,829,000 and HKD 5,824,000 respectively[10] - Future business operations may be impacted by ongoing global economic challenges, but the company aims to improve business models and expand product offerings for organic growth[24] Corporate Governance - The company confirmed compliance with the standard code for securities trading by all directors for the six months ended June 30, 2024[37] - The company is committed to maintaining high levels of corporate governance and has adhered to the corporate governance code provisions, except for the vacancy in the CEO position[38] - The audit committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the six months ended June 30, 2024, which were not audited by the company's auditor but deemed compliant with applicable accounting standards[39] Share Incentive Plan - The company adopted a share incentive plan on June 19, 2015, with a duration of 10 years to recognize contributions from eligible participants[36] - As of June 30, 2024, the company has not granted any share incentives to any individuals under the share incentive plan[36] Dividends - The company did not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous year[14] Costs and Expenses - The company recognized a cost of goods sold of HKD 19,914,000, significantly higher than HKD 9,206,000 in the previous year[13] - Interest income from bank balances was reported at HKD 0 for the six months ended June 30, 2024, down from HKD 153,000 in 2023[11] Capital Commitments - The group had no significant capital commitments or contingent liabilities as of June 30, 2024[28]
京玖康疗(00648) - 2024 - 中期业绩